Silo Pharma Inc (SILO)

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial

Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development...

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a...

Form 8-K - Current report

Form 8-K - Current report

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation...

Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel...

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward...

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form POS AM - Post-Effective amendments for registration statement

Form EFFECT - Notice of Effectiveness